DaVita (NYSE:DVA) Sets New 12-Month High – Should You Buy?

Shares of DaVita Inc. (NYSE:DVA) hit a new 52-week high during trading on Friday . The company traded as high as $157.49 and last traded at $157.1610, with a volume of 337492 shares traded. The stock had previously closed at $152.54.

Analyst Upgrades and Downgrades

DVA has been the subject of several recent analyst reports. Barclays boosted their target price on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Truist Financial set a $158.00 price target on shares of DaVita in a research report on Thursday, February 5th. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Finally, TD Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, DaVita has an average rating of “Hold” and an average price target of $155.80.

DaVita Stock Performance

The stock has a market capitalization of $10.49 billion, a PE ratio of 15.84, a price-to-earnings-growth ratio of 0.52 and a beta of 0.99. The business’s 50-day moving average is $123.36 and its two-hundred day moving average is $125.82.

DaVita (NYSE:DVA) last released its earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter last year, the business earned $2.24 EPS. The business’s revenue was up 9.9% on a year-over-year basis. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Equities analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

Institutional Trading of DaVita

A number of institutional investors have recently modified their holdings of the business. Invesco Ltd. lifted its holdings in DaVita by 2.0% in the third quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after acquiring an additional 32,358 shares during the period. Morgan Stanley lifted its stake in shares of DaVita by 5.1% in the fourth quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock valued at $167,807,000 after purchasing an additional 71,156 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in DaVita by 114.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after buying an additional 636,191 shares in the last quarter. Dimensional Fund Advisors LP grew its position in DaVita by 0.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,089,100 shares of the company’s stock worth $123,733,000 after buying an additional 3,507 shares during the period. Finally, LSV Asset Management grew its position in DaVita by 1.1% during the fourth quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after buying an additional 9,739 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.